Answers are grounded in this paper and cite their sources.
This review explores challenges in enzyme modulation and drug repurposing, highlighting implications for drug design.
The cross-reactivity of substrates, modulators with other enzymes significantly reduces/prevents our ability to design such highly specific, that is, "one warhead-one target", modulators. On the other hand, the potential "impasse" fuels repurposing of already developed drugs. Additionally, expanding our understanding that there will be "off-target" effects for enzymes of different evolutionary kingdoms propels the development of covalent reversible drugs. In this review/perspective, we examine these challenges and opportunities based on covalent drugs used/developed for targeting bacterial and mammalian enzymes, and our evolving understanding of the blurred difference between these enzymes in these "vastly" separated organisms by biological evolution.
No takes yet. Share an insight, caveat, or question.
Konaklieva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: